- Pall's (PLL-OLD +0.3%) Q1 earnings results are so impressive that Danaher (DHR -0.1%), who is seeking to buy the filtration and purification company, is "looking brilliant," Janney analysts say.
- Pall showed acceleration across all business lines, with organic growth reaching 9% vs. expectations of 5%, Janney says, adding it is particularly encouraged by the acceleration in the Life Science business, which reached 10.4% growth in the BioPharm division.
- DHR has finally transformed itself into a pure-play Life Science company as it splits off its Industrial division, and with high exposure to the next decade of growth in biological production, diagnostics and Asia, Danaher Life Science will be "a bouquet of growth businesses," the firm says.